Alnylam Pharmaceuticals, Inc. ALNY

ALNY Company Overview

Alnylam Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company operates primarily within the biopharmaceutical and genetic medicines industries, developing therapies designed to silence disease-causing genes at the messenger RNA level. Alnylam’s core revenue drivers include commercialized RNAi therapies for rare genetic and cardio-metabolic diseases, collaboration revenues from pharmaceutical partnerships, and milestone payments tied to research and development programs.

The company’s commercial portfolio includes products such as ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), and Leqvio under a collaboration arrangement with Novartis. Alnylam primarily serves patients with rare diseases, specialty healthcare providers, and global pharmaceutical partners. Its strategic positioning is based on its early leadership in RNAi therapeutics, extensive intellectual property portfolio, and proprietary delivery technologies, particularly for hepatic targeting. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam evolved from a research-focused RNAi platform company into one of the first firms to achieve broad commercial validation of RNAi-based medicines through multiple regulatory approvals in the United States, Europe, and other international markets.